Johannes Kalbhenn, Feline Gabler, Sebastian Heinrich, Daniel Steinmann
{"title":"[用载体疫苗ChAdOx1-S(阿斯利康COVID-19疫苗)免疫SARS-CoV-2后的主观幸福感和工作能力]。","authors":"Johannes Kalbhenn, Feline Gabler, Sebastian Heinrich, Daniel Steinmann","doi":"10.1007/s40664-021-00448-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The SARS coronavirus 19 vaccine ChAdOx1‑S (Vaxzevria, AstraZeneca) has been licensed since January 2021 by the Paul Ehrlich Institute for Germany. In several campaigns, healthcare workers and medical students were offered this vaccine on a voluntary basis.</p><p><strong>Aim: </strong>The primary endpoint of the study was to assess the rate and duration of the incapacity to work as a result of initial immunization with ChAdOx1‑S. Secondary endpoints were type and severity of adverse events and self-perceived tolerability.</p><p><strong>Material and methods: </strong>Anonymized online questionnaire to be completed once by all vaccinated individuals after receiving the first dose of ChAdOx1‑S. The severity of side effects was queried using an ordinal numerical rating scale with values ranging from 0 to 10. Other key data points were age, sex, and occupational group. Ability to work in the days following the injection was also assessed by self-reporting.</p><p><strong>Results: </strong>Data from 1988 respondents were analyzed. The mean age was 37.13 years (standard deviation 13.7 years). Of the respondents 69.8% were female, 48.1% belonged to therapeutic and technical professions with patient contact, 38% were students, 10.6% were nursing personnel and 4% were physicians. Only 14.4% of respondents reported having tolerated the vaccination without side effects. The most common side effect was fatigue, followed by pain at the injection site. This was followed in descending frequency by headache, aching limbs, and chills. After vaccination 18% of respondents felt able to return to work immediately, 51% of all respondents had to report themselves unfit for work for at least 1 day after vaccination. Side effects were more prevalent in male and younger respondents.</p><p><strong>Conclusion: </strong>Vaccination with ChAdOx1‑S frequently resulted in side effects. These resulted in 37% of respondents reporting sick. Nevertheless, 89.6% of all respondents would choose coronavirus vaccination with ChAdOx1‑S again.</p>","PeriodicalId":43038,"journal":{"name":"Zentralblatt fur Arbeitsmedizin Arbeitsschutz und Ergonomie","volume":"72 2","pages":"51-57"},"PeriodicalIF":0.3000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572530/pdf/","citationCount":"0","resultStr":"{\"title\":\"[Subjective well-being and ability to work after SARS-CoV-2 immunization with the vector vaccine ChAdOx1-S (AstraZeneca COVID-19 vaccine)].\",\"authors\":\"Johannes Kalbhenn, Feline Gabler, Sebastian Heinrich, Daniel Steinmann\",\"doi\":\"10.1007/s40664-021-00448-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The SARS coronavirus 19 vaccine ChAdOx1‑S (Vaxzevria, AstraZeneca) has been licensed since January 2021 by the Paul Ehrlich Institute for Germany. In several campaigns, healthcare workers and medical students were offered this vaccine on a voluntary basis.</p><p><strong>Aim: </strong>The primary endpoint of the study was to assess the rate and duration of the incapacity to work as a result of initial immunization with ChAdOx1‑S. Secondary endpoints were type and severity of adverse events and self-perceived tolerability.</p><p><strong>Material and methods: </strong>Anonymized online questionnaire to be completed once by all vaccinated individuals after receiving the first dose of ChAdOx1‑S. The severity of side effects was queried using an ordinal numerical rating scale with values ranging from 0 to 10. Other key data points were age, sex, and occupational group. Ability to work in the days following the injection was also assessed by self-reporting.</p><p><strong>Results: </strong>Data from 1988 respondents were analyzed. The mean age was 37.13 years (standard deviation 13.7 years). Of the respondents 69.8% were female, 48.1% belonged to therapeutic and technical professions with patient contact, 38% were students, 10.6% were nursing personnel and 4% were physicians. Only 14.4% of respondents reported having tolerated the vaccination without side effects. The most common side effect was fatigue, followed by pain at the injection site. This was followed in descending frequency by headache, aching limbs, and chills. After vaccination 18% of respondents felt able to return to work immediately, 51% of all respondents had to report themselves unfit for work for at least 1 day after vaccination. Side effects were more prevalent in male and younger respondents.</p><p><strong>Conclusion: </strong>Vaccination with ChAdOx1‑S frequently resulted in side effects. These resulted in 37% of respondents reporting sick. Nevertheless, 89.6% of all respondents would choose coronavirus vaccination with ChAdOx1‑S again.</p>\",\"PeriodicalId\":43038,\"journal\":{\"name\":\"Zentralblatt fur Arbeitsmedizin Arbeitsschutz und Ergonomie\",\"volume\":\"72 2\",\"pages\":\"51-57\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572530/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zentralblatt fur Arbeitsmedizin Arbeitsschutz und Ergonomie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s40664-021-00448-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/11/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zentralblatt fur Arbeitsmedizin Arbeitsschutz und Ergonomie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40664-021-00448-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/11/7 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
[Subjective well-being and ability to work after SARS-CoV-2 immunization with the vector vaccine ChAdOx1-S (AstraZeneca COVID-19 vaccine)].
Background: The SARS coronavirus 19 vaccine ChAdOx1‑S (Vaxzevria, AstraZeneca) has been licensed since January 2021 by the Paul Ehrlich Institute for Germany. In several campaigns, healthcare workers and medical students were offered this vaccine on a voluntary basis.
Aim: The primary endpoint of the study was to assess the rate and duration of the incapacity to work as a result of initial immunization with ChAdOx1‑S. Secondary endpoints were type and severity of adverse events and self-perceived tolerability.
Material and methods: Anonymized online questionnaire to be completed once by all vaccinated individuals after receiving the first dose of ChAdOx1‑S. The severity of side effects was queried using an ordinal numerical rating scale with values ranging from 0 to 10. Other key data points were age, sex, and occupational group. Ability to work in the days following the injection was also assessed by self-reporting.
Results: Data from 1988 respondents were analyzed. The mean age was 37.13 years (standard deviation 13.7 years). Of the respondents 69.8% were female, 48.1% belonged to therapeutic and technical professions with patient contact, 38% were students, 10.6% were nursing personnel and 4% were physicians. Only 14.4% of respondents reported having tolerated the vaccination without side effects. The most common side effect was fatigue, followed by pain at the injection site. This was followed in descending frequency by headache, aching limbs, and chills. After vaccination 18% of respondents felt able to return to work immediately, 51% of all respondents had to report themselves unfit for work for at least 1 day after vaccination. Side effects were more prevalent in male and younger respondents.
Conclusion: Vaccination with ChAdOx1‑S frequently resulted in side effects. These resulted in 37% of respondents reporting sick. Nevertheless, 89.6% of all respondents would choose coronavirus vaccination with ChAdOx1‑S again.
期刊介绍：
Zielsetzung der Zeitschrift Das Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie ist eine der ältesten deutschsprachigen wissenschaftlichen Fachzeitschriften im Bereich Arbeit, Umwelt, Gesundheit und Sicherheit. Es bietet ein Forum für frei eingereichte Originalartikel, Übersichten, Short Communications und Kasuistiken. Die Fachzeitschrift ermöglicht einen wissenschaftlichen Erfahrungsaustausch und stellt optimale Problemlösungen zur Verfügung. Die Zielgruppen der Zeitschrift sind Arbeitsmediziner, Sozialmediziner, Umweltmediziner, Sicherheitsingenieure, Arbeitswissenschaftler sowie andere Gruppen und Institutionen, die eng mit der Arbeits-, Sozial- und Umweltmedizin sowie dem Arbeitsschutz und der Ergonomie verbunden sind. Durch vertiefende Forschungsartikel und Übersichten werden Fachpersonen aus der Arbeits-, Sozial- und Umweltmedizin über neue medizinische Entwicklungen und Gesetze in der Prävention, Diagnose und Rehabilitation von umweltbedingten Erkrankungen und arbeitsbedingten Verletzungen und Erkrankungen auf dem Laufenden gehalten. Originalarbeiten und Übersichten liefern Ergebnisse der aktuellen Forschung und deren Integration in die tägliche Praxis. Die Spanne der Themen reicht dabei von toxikologischen Fragestellungen über die Reise- und Tropenmedizin und Public-Health-Aspekten bis hin zur Versorgungsforschung und Ergonomie. Aims & Scope Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie is one of the oldest scientific journals devoted to the field of work, environment, health and safety, edited in the German language. It offers a forum for freely submitted original articles, reviews, short communications and case reports. The journal enables a scientific exchange of experience and provides optimal solutions to problems. The target groups of the journal are occupational physicians, safety engineers, occupational scientists and other groups and institutions closely related to occupational, safety and environmental medicine as well as industrial safety and ergonomics. In-depth research articles and reviews keep occupational, social and environmental medicine professionals up to date on new medical developments and laws in the prevention, diagnosis and rehabilitation of environmentally induced conditions and work-related injuries and illnesses. Original papers and review articles provide results of the current research and their integration into daily practice. Topics range from the fields of toxicology, travel/tropical medicine and public health aspects to health services research and ergonomics. Review: All articles of Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie undergo a peer review process. Declaration of Helsinki: All manuscripts submitted for publication presenting results from studies on probands or patients must comply with the Declaration of Helsinki. Indexed in Emerging Sources Citation Index (ESCI), Embase and Scopus
![[Subjective well-being and ability to work after SARS-CoV-2 immunization with the vector vaccine ChAdOx1-S (AstraZeneca COVID-19 vaccine)].](https://img.booksci.cn/booksciimg/2022-1/2024030678242616504749608593689.jpg)
![[Subjective well-being and ability to work after SARS-CoV-2 immunization with the vector vaccine ChAdOx1-S (AstraZeneca COVID-19 vaccine)].](https://img.booksci.cn/booksciimg/2022-1/2024030678258346532197410425788.jpg)
![[Subjective well-being and ability to work after SARS-CoV-2 immunization with the vector vaccine ChAdOx1-S (AstraZeneca COVID-19 vaccine)].](https://img.booksci.cn/booksciimg/2022-1/202403067828181612982491545038.jpg)
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
